113 related articles for article (PubMed ID: 33682222)
1. Salivary BPIFA proteins are altered in patients undergoing hematopoietic cell transplantation.
Innocentini LMAR; Silva AA; Carvalho MA; Coletta RD; Corrêa MEP; Bingle L; Bingle CD; Vargas PA; Lopes MA
Oral Dis; 2022 May; 28(4):1279-1288. PubMed ID: 33682222
[TBL] [Abstract][Full Text] [Related]
2. Subjective Oral Dryness following Hematopoietic Cell Transplantation: A Report from the Orastem Study.
Bulthuis MS; van Leeuwen SJM; Thomas RZ; van Gennip LLA; Whiteside HM; Isom S; Kline DM; Laheij AMGA; Raber-Durlacher JE; Hasséus B; Johansson JE; Hovan AJ; Brennan MT; von Bültzingslöwen I; Huysmans MDNJM; Blijlevens NMA
Transplant Cell Ther; 2024 Apr; 30(4):446.e1-446.e11. PubMed ID: 38242439
[TBL] [Abstract][Full Text] [Related]
3. The effect of conditioning regimen and prescribed medications on hyposalivation in haematopoietic cell transplantation (HCT) patients: an 18-month prospective longitudinal study.
Bulthuis MS; van Gennip LLA; Thomas RZ; Bronkhorst EM; Laheij AMGA; Raber-Durlacher JE; Rozema FR; Brennan MT; von Bültzingslöwen I; Blijlevens NMA; Huysmans MDNJM; van Leeuwen SJM
Clin Oral Investig; 2023 Dec; 27(12):7369-7381. PubMed ID: 37853264
[TBL] [Abstract][Full Text] [Related]
4. Salivary BPIFA1 (SPLUNC1) and BPIFA2 (SPLUNC2 A) are modified by head and neck cancer radiotherapy.
González-Arriagada WA; Ramos LM; Silva AA; Vargas PA; Coletta RD; Bingle L; Lopes MA
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Jan; 119(1):48-58. PubMed ID: 25482547
[TBL] [Abstract][Full Text] [Related]
5. Salivary antioxidant enzymes associated with oral toxicity in haematopoietic cell transplantation: An observational study.
Bezinelli LM; Eduardo FP; Ferreira MH; Gobbi M; Lopes RMG; Rosin FCP; Vogel C; Hamerschlak N; Corrêa L
Eur J Clin Invest; 2021 Feb; 51(2):e13379. PubMed ID: 32959899
[TBL] [Abstract][Full Text] [Related]
6. Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation.
Imanguli MM; Atkinson JC; Harvey KE; Hoehn GT; Ryu OH; Wu T; Kingman A; Barrett AJ; Bishop MR; Childs RW; Fowler DH; Pavletic SZ; Hart TC
Exp Hematol; 2007 Feb; 35(2):184-92. PubMed ID: 17258067
[TBL] [Abstract][Full Text] [Related]
7. Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study.
Soejima T; Shiohara M; Ishida Y; Inoue M; Hayakawa A; Sato A; Kamibeppu K; Atsuta Y; Yamashita T
Int J Hematol; 2021 Apr; 113(4):566-575. PubMed ID: 33386599
[TBL] [Abstract][Full Text] [Related]
8. Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease.
Fall-Dickson JM; Mitchell SA; Marden S; Ramsay ES; Guadagnini JP; Wu T; St John L; Pavletic SZ;
Biol Blood Marrow Transplant; 2010 Jul; 16(7):948-956. PubMed ID: 20139026
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic Exposure, Not Alloreactivity, Is the Major Driver of Microbiome Changes in Hematopoietic Cell Transplantation.
Bansal R; Park H; Taborda CC; Gordillo C; Mapara MY; Assal A; Uhlemann AC; Reshef R
Transplant Cell Ther; 2022 Mar; 28(3):135-144. PubMed ID: 34958974
[TBL] [Abstract][Full Text] [Related]
10. Parotid salivary gland dysfunction in chronic graft-versus-host disease (cGVHD): a longitudinal study in a mouse model.
Levy S; Nagler A; Okon S; Marmary Y
Bone Marrow Transplant; 2000 May; 25(10):1073-8. PubMed ID: 10828868
[TBL] [Abstract][Full Text] [Related]
11. Evolution of Body Composition Following Autologous and Allogeneic Hematopoietic Cell Transplantation: Incidence of Sarcopenia and Association with Clinical Outcomes.
DeFilipp Z; Troschel FM; Qualls DA; Li S; Kuklinski MW; Kempner ME; Hochberg E; Chen YB; El-Jawahri A; Fintelmann FJ
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1741-1747. PubMed ID: 29496561
[TBL] [Abstract][Full Text] [Related]
12. Quantitative salivary proteomic differences in oral chronic graft-versus-host disease.
Bassim CW; Ambatipudi KS; Mays JW; Edwards DA; Swatkoski S; Fassil H; Baird K; Gucek M; Melvin JE; Pavletic SZ
J Clin Immunol; 2012 Dec; 32(6):1390-9. PubMed ID: 22806177
[TBL] [Abstract][Full Text] [Related]
13. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
14. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
Kharfan-Dabaja MA; Al Malki MM; Deotare U; Raj RV; El-Jurdi N; Majhail N; Cherry MA; Bashir Q; Darrah J; Nishihori T; Sibai H; Hamadani M; de Lima M; Gerds AT; Selby G; Qazilbash MH; Forman SJ; Ayala E; Lipton JH; Hari PN; Muzzafar T; Zhang L; Olteanu H; Perkins J; Sokol L; Kumar A; Ahmed S
Br J Haematol; 2017 Dec; 179(5):781-789. PubMed ID: 28980314
[TBL] [Abstract][Full Text] [Related]
15. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
[TBL] [Abstract][Full Text] [Related]
16. The parotid secretory protein BPIFA2 is a salivary surfactant that affects lipopolysaccharide action.
Nandula SR; Huxford I; Wheeler TT; Aparicio C; Gorr SU
Exp Physiol; 2020 Aug; 105(8):1280-1292. PubMed ID: 32390232
[TBL] [Abstract][Full Text] [Related]
17. Post-allogeneic Hematopoietic Stem Cell Transplantation (HSCT) changes in inorganic salivary components.
Boer CC; Correa ME; Tenuta LM; Souza CA; Vigorito AC
Support Care Cancer; 2015 Sep; 23(9):2561-7. PubMed ID: 25652148
[TBL] [Abstract][Full Text] [Related]
18. Impact of donor and recipient characteristics on graft-versus-host disease and survival in HLA-matched sibling hematopoietic stem cell transplantation.
Zhang H
Transfus Apher Sci; 2020 Jun; 59(3):102743. PubMed ID: 32139282
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis.
Bachier CR; Aggarwal SK; Hennegan K; Milgroom A; Francis K; Dehipawala S; Rotta M
Transplant Cell Ther; 2021 Jun; 27(6):504.e1-504.e6. PubMed ID: 34158154
[TBL] [Abstract][Full Text] [Related]
20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
